Audit: QRS - Tribulus terrestris for Health & Longevity
Audit conducted on 12/08/2026 05:23 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER lines 362/368/374; time cells to ER lines 417 and 157; benefits/risks to ER benefit and risk headings; gates to ER lines 307–340; monitoring table and cadence to ER lines 447–462. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_12_target carries the ER’s “No established functional target; track change from the individual’s own baseline” verbatim. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain absolute framing; “Higher total testosterone in low-androgen groups” keeps the population restriction rather than generalising. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Both gates draw only from ER Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor content appears. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names (Tribestan, Sopharma, Herbarium) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, sceptical register of the ER Conclusion is carried through, including the manufacturer-funding caveat. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds throughout, with plain-language framing in At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as observed trial practice, not as instruction to the reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “recommend”, “advise”, “consult”, “should” or “must” appears in the QRS. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Cadence and protocol cells describe trial regimens rather than prescribing them. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns occur anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Abbreviations are expanded on first use in the Monitoring table (SHBG, LH, ALT/AST, eGFR, PSA, HbA1c, CK); remaining technical terms are ER-verbatim gate labels. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are reduced to a key fact plus qualifier; no prose paragraphs outside At-A-Glance and Cadence. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address anywhere in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Twelve-marker panel, functional ranges and interaction list assume a proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Thrice-daily dosing for 12 weeks and repeated lab panels are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional (not conventional) reference ranges and a full baseline panel place it beyond general-population content. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance leads with the failure of the testosterone claim, the signal most relevant to this audience’s likely reason for interest. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “tablets”, “extract”, “gastrointestinal intolerance”, “rhabdomyolysis”, “priapism” — clinical register maintained outside the deliberately plain At-A-Glance. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All verified verbatim at lines 446, 492, 541, 571, 595, 625, 653, 657–659, 849 and in the four tier <strong> labels of Benefits and Risks. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; the repeatable marker_#_* and qualitative_item_# spans are instantiated as marker_1–12 and qualitative_item_1–7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against [qrs_template] shows no change outside the variable spans — CSS, wrapper markup, website= spans, footer disclaimer and the template’s own comments are byte-identical in content. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relied on by the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standardized-extract protocol”, “Women’s protocol”, “Split versus single dose” and all twelve interaction labels reproduce the ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect cell labels are the only derived labels, and no ER bold label exists for those sub-facts. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur in the file; the ER’s “⚠️ Conflicted” markers are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Template page geometry is untouched; every section is condensed to key facts with rationale, citations and parentheticals stripped, subject to the completeness mandates of 8.2, 9.2, 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; it is the first element after the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: tribulus_terrestris_2026-0812-0206_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching this prompt. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0812-0459. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all eight fields; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Tribulus terrestris for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Tribulus terrestris for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/12/2026”, matching qrs_creation_date 2026-0812-0459. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Covers the failed hormone claim, what does hold up, the timeframe, the trial-quality caveat and the product-quality caveat — all from ER lines 492–496. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence at ER lines 492, 494 and 496. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “hormone levels”, “blood flow”, “sperm quality” used in place of clinical terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric outcome data appear; only the qualitative “modest improvement”. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to the “Populations who should avoid Tribulus terrestris” list at ER lines 333–340. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 574–590: eight discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationales stripped, e.g. ER “(no human safety data…)” and “, given documented product contamination” do not appear; no trailing dash clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “at any stage”, “above 4 ng/mL”, “Child-Pugh Class B or C”, “above twice the upper reference limit”, “below 30 mL/min/1.73 m²” and “under 18” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; thresholds are written out as “above”/”below”. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names eight such populations and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All twelve items trace to the bulleted interaction list at ER lines 307–329. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All twelve ER interaction bullets present; tacrolimus and cyclosporine are correctly withheld from item 2 because transplant immunosuppressants are already a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 598–615: twelve discrete <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is label plus example-drug parenthetical only; the ER’s “Caution.”/”Monitor.” verdicts and mitigation sentences are all stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Ten of twelve items carry their ER drug list verbatim; the PDE5 and CYP3A4-substrate lists are trimmed but retain named examples. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s parentheticals are plain comma-separated drug lists with no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names twelve interactions and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol bullets at lines 362, 368 and 374. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The trial-validated dosing regimen, the female regimen, and dose splitting — the three bullets that determine what is actually taken and how. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains twelve bullets; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine of nine cells populated; labels are ER bold labels and values/subs restate ER dose, standardization, duration and timing. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Erectile function, desire in women and semen parameters — the three benefit domains for which the ER states a timeframe. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Erectile function (High tier) first, then the two Medium-tier benefits in the ER’s own order. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Nine of nine cells populated from ER lines 417 (30/90 days, 12 weeks, nothing inside 2 weeks) and 157 (one to three months in women). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten benefit entries correspond one-to-one with the ER Expected Benefits sub-headings at lines 147–207. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 543–564, tier-matched to the ER. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER sub-heading only; no Magnitude figures, mechanisms or trial references carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits entry; the ER’s “⚠️ Conflicted” markers are also dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | The ER populates all four benefit tiers, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All nine risk entries correspond one-to-one with the ER risk sub-headings at lines 233–287. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 627–647, tier-matched to the ER. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER sub-heading only; no bilirubin/creatinine peaks, case ages or incidence notes carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | ER “Priapism (Prolonged Painful Erection)” reduced to “priapism”; no parentheses remain in any risks entry. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | The ER populates all four risk tiers, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table at lines 449–462. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All twelve ER biomarkers present in ER order, with Optimal Functional Range and Why Measure It? carried across verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 838–843 reproduce the ER cadence of line 447: baseline, 4 weeks, 12 weeks, every 6 months, plus the immediate re-test trigger. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All seven items trace to the “Qualitative markers worth tracking alongside the labs” list at ER lines 466–472. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Seven of seven ER qualitative markers present in ER order, none added. |
Issues 12/08/2026 05:23
Pass rate 100.00%. No issues found.
Issues 12/08/2026 05:15
- 2.15 — Colloquial term for gut irritation: [action_3_sub] (QRS line 486) says the split dose “spreads the saponin load that irritates the gut”, replacing the ER’s formal “causes gastrointestinal irritation” (ER line 374) with consumer-grade wording in the document’s own voice.
Fixes 12/08/2026 05:15
- 2.15 — Colloquial term for gut irritation: Changed [action_3_sub] from “spreads the saponin load that irritates the gut” to “spreads the saponin load that causes gastrointestinal irritation”, matching the ER’s formal wording.
Issues 12/08/2026 05:07
- 1.1 / 1.3 — Unqualified testosterone claim: [at_a_glance] (line 434) states the extract “does not raise hormone levels” without the ER’s population scope (“across controlled studies in healthy and athletic men, hormone levels … are unchanged”), which strengthens the ER claim and contradicts the QRS’s own Benefits line “Higher total testosterone in low-androgen groups” (line 554).
Fixes 12/08/2026 05:07
- 1.1 / 1.3 — Unqualified testosterone claim: In [at_a_glance], “does not raise hormone levels” was changed to “does not raise already-normal hormone levels”, restoring the ER’s population scope and removing the contradiction with the Benefits line “Higher total testosterone in low-androgen groups”. The section remains within the 60-word limit at 59 words.